Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
- Psychedelics Beyond MAHA?
- What ICER’s Spravato Review Might Mean for Compass’ Psilocybin
- Judge Dismisses DemeRx’s Ibogaine Suit Against atai, for Now
- FDA Updates House Caucus on Psychedelics, Clarifies Limits of SPAs
- Judge Sends Terran’s Trade Secrets Suit Against Compass to Trial
- Other Stories
- Half of Registered Spravato Sites Treated Patients in Past Six Months
- Jocasta Options Diamond’s Non-Hallucinogenic 5-HT2A Agonists
- Usona Surprises Some; Real Race Starts After Any Approval
- Cohen’s Bill Would Rewrite Drug Scheduling
- Other Headlines
Psychedelics Beyond MAHA?
Following the Democrats’ sweeping success in Tuesday’s elections, some in the field may wonder what the elections might mean for psychedelics and the support they appear to have found within the current administration.
The Make America Healthy Again (MAHA) movement, which has championed psychedelics as one of its interest areas, also suffered losses, with allies in states like Kansas and Iowa losing to Democratic competitors. Those include Zach Lahn, whom MAHA had backed for Iowa Governor, with the ‘Make Iowa Healthy Again’ slogan used at some rallies. He lost to Democrat Rob Sand. And Roger Marshall, who founded and chaired the Congressional MAHA Caucus, lost a Senate race in Kansas to Democrat Adam Hamilton...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks